High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure
Sponsor: Relypsa, Inc.
Listed as NCT02823626, this observational or N/A phase trial focuses on Acute Decompensated Heart Failure and remains completed. Sponsored by Relypsa, Inc., it has been updated 8 times since 2016, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2019 — Jan 2021 [monthly]
Completed
Phase: NA → None
-
Jun 2018 — Jun 2019 [monthly]
Completed NA
▶ Show 3 earlier versions
-
May 2018 — Jun 2018 [monthly]
Completed NA
Status: Recruiting → Completed
-
Feb 2017 — May 2018 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting NA
First recorded
Sep 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Relypsa, Inc.
- The University of Texas Health Science Center at San Antonio
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • San Antonio, United States